Do I need to take afatinib all the time? Drug discontinuation criteria and drug resistance judgment

Afatinib is a second-generation EGFR tyrosine kinase inhibitor that is widely used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR mutations, especially common types such as exon 19 deletion or 21 L858R mutation. Many patients are often concerned during the treatment process: Does afatinib need to be taken long-term? Is there a clear withdrawal time? In fact, the treatment concept of this type of targeted drugs is not "short-term cure", but "continuous control", so it generally needs to be taken for a long time until disease progression or unacceptable toxic reactions occur.

Afatinib controls tumor growth by continuously inhibiting theEGFR signaling pathway, and its effect relies on stable blood concentration and continuous blockade. Therefore, it is not recommended to discontinue medication at will in most patients before drug resistance or toxic reactions are clear. If the patient interrupts treatment privately, even if the lesion is temporarily stable, the tumor may still rebound rapidly due to the restoration of the pathway. There are two main reasonable times to discontinue the drug: first, when imaging evaluation shows clear progression of the disease, that is, the emergence of new lesions or expansion of the primary tumor; second, when serious drug-related adverse reactions occur, such as persistent diarrhea, rash, elevated liver enzymes, etc., and are still intolerable after dose adjustment.

The criteria for judging drug resistance are usually based on imaging evidence of disease progression and changes in clinical symptoms, supplemented by genetic testing. For example, if a patient's tumor re-grows after using afatinib for a period of time, the doctor may recommend re-testing for EGFR, MET, HER2 and other targets to determine whether new drug-resistant mutations have occurred, such as T790M, C797S, etc., which will help decide whether to switch to osimertinib or other third-generation EGFR-TKIs.

It should be noted that even if the drug is stopped, the transition should be gradual under the guidance of a doctor and should not be interrupted suddenly. For some patients whose condition is stable but who are worried about long-term side effects, doctors may also recommend an "intermittent treatment" strategy, but this approach requires strict individualized management.

Reference materials:https://www.giotrif.com/